image

ISSN: 1935-1232 (P)

ISSN: 1941-2010 (E)

image
image

Abstract

Putative/New Antipsychotics

Author(s): Peter F. Buckley

The U.S. Food and Drug Administration (FDA) has approved lurasidone for use in adolescents (aged 13–17 years) with schizophrenia. The FDA’s extension of lurasidone to the adolescent population was based on the positive efficacy results from a six-week, placebo-controlled trial of 40 or 80 mg/day. Both doses of lurasidone were effective.